HP-228

N/A

Report date: 2022/02/17 13:51:51
NME

Base Information

Drug NameHP-228
Drug Alias NameILP-228HP-228
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-1 alpha inhibitorsNitric-oxide synthase, brain inhibitorsNitric-oxide synthase, endothelial inhibitors +[6] 
TargetsInterleukin-1 alphaNitric-oxide synthase, brainNitric-oxide synthase, endothelial +[6] 
Therapy Area/IndicationsPain, PostoperativeInflammationObesity +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSYGNIS Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSYGNIS Pharma
Active IndicationsN/A
Inactive IndicationsPain, PostoperativeInflammationObesity +[4] 

Other Information

ATC CodeN/A
Related LinksN/A